Meta-Analysis
Copyright ©The Author(s) 2025.
World J Stem Cells. Jul 26, 2025; 17(7): 108202
Published online Jul 26, 2025. doi: 10.4252/wjsc.v17.i7.108202
Table 1 Glycemic outcomes in each of the studies that are chosen for assessing eligibility for meta-analysis
Ref.
Type of study
HbA1c
FBG
C-peptide levels
PBG
Insulin requirements
Randomized
Non-randomized
Blindness
Prospective
Retrospective
Parallel
Cross over
Cai et al[12]1+NB++++++
Packham et al[13]1+DB+++
Carlsson et al[14]1+NB+++++
Leão et al[15]1+NB+++
Skyler et al[16]1+SB++++
Thakkar et al[17]1+NB+++++++
Zhao et al[18]1+NB++++
Wu et al[19]1+NB++++++
Wu et al[20]1+NB++++++
Vanikar et al[21]2+NB+++++++
Bhansali et al[22]2+SB++++++
Hu et al[23]2+SB++++++
Hu et al[24]2+DB+++++++
Jiang et al[25]2+NB+++++
Li et al[26]2+NB++++++
Lian et al[27]2+NB++++++
Liu et al[28]2+NB+++++++
Moon et al[29]2+SB+++++
Nguyen et al[30]2+NB++++++
De Guzman et al[31]2+NB++++
Guan et al[32]2+NB++++
Purwati et al[33]2+NB+++++
Table 2 Detailed information about the characteristics of mesenchymal stem cells that are used in studies that underwent meta-analysis, and the various methods by which mesenchymal stem cells are grafted
Ref.
Source of MSCs
Type of graft of MSCs
Type of grafting method of MSCs
Targeted tissue/organ
Cai et al[12]UC-MSCs and aBM-MNCsAllogeneicIntra-arterial infusion via supra-selective pancreatic artery cannulationPancreas
Packham et al[13]BM-MPCsAllogeneicIV infusionKidneys
Carlsson et al[14]BM-MSCsAutologousIV infusionPancreas
Leão et al[15]ASCsAllogeneicIV infusionSystemic administration
Skyler et al[16]BM-MPCsAllogeneicIV infusionSystemic administration
Thakkar et al[17]IS-AD-MSCs and BM-HSCsAutologousInfusion into the portal vein, thymic circulation, and subcutaneous tissuePancreas and subcutaneous tissue
Zhao et al[18]CB-SCsAllogeneicStem cell educator therapyPancreas
Re-infusion of educated lymphocytes into the patient’s circulation
Wu et al[19]BM-MNCsAutologousPancreatic intra-arterial infusion via the dorsal pancreatic arteryPancreas
Wu et al[20]BM-MSCsAutologousIntra-arterial and intravenous infusionPancreas
Table 3 The reasons for the usage of different sources for extracting mesenchymal stromal cells in order to treat diabetes mellitus[45]
MSC source
Proliferation rate
Immunomodulation
Angiogenesis
Differentiation potential
Clinical applications in diabetes
BM-MSCsModerateStrongModerateOsteogenic, adipogenic, chondrogenicImmune modulation, islet transplantation support
AD-MSCsHighStrongHighAdipogenic, osteogenic, chondrogenicInsulin sensitivity, wound healing
UC-MSCsVery highStrongestHighOsteogenic, chondrogenic, myogenicAutoimmune diabetes (T1DM), regenerative therapy
WJ-MSCsVery highStrongestHighOsteogenic, chondrogenic, myogenicβ-cell protection, allogeneic therapy
PD-MSCsHighStrongVery highMultipotentβ-cell protection, neuroprotection, tissue repair